Updated

Updated · The New York Times · Aug 24

Melissa Whitney's 354-Page 'The Recovery Run' Centers Visually Impaired Marathoner

Updated

Updated · The New York Times · Aug 24

Melissa Whitney's 354-Page 'The Recovery Run' Centers Visually Impaired Marathoner

Q: With a breakthrough Stargardt treatment nearing FDA approval in 2027, will the lived reality in this groundbreaking romance novel soon become history?

No. Even if an FDA approval arrives in 2027, *The Recovery Run*’s depiction of Stargardt disease is unlikely to become “history” anytime soon. The treatment closest to market, Belite Bio’s oral tinlarebant, has an FDA Priority Review decision date of Feb. 12, 2027. But the Phase 3 data behind it show slowing of disease progression—not a cure. The company reported a 35.7% reduction in growth of retinal lesions versus placebo, and the drug is aimed at limiting further retinal damage, not restoring vision already lost. That means people already living with central vision loss would still face many of the daily realities Melissa Whitney puts on the page. The same is true of Alkeus’s gildeuretinol, another promising oral therapy now in a pivotal Phase 3 trial. Its goal is also to slow lesion growth and preserve function, including low-light vision. It remains investigational, and even if successful, it would not erase the need for mobility skills, guide running, disability services, and the kinds of trust and communication the novel centers. There is real medical progress. Stargardt disease, a rare inherited retinal disorder affecting roughly 50,000 to 60,000 Americans, has had no approved treatment. A first approval would be a major turning point. But access, timing of diagnosis, eligibility, age, stage of disease, and uneven treatment response all matter. So the book’s “lived reality” is better understood as current and likely durable, even in a more hopeful treatment era.

1 articles · Updated · The New York Times · Aug 24

$20 paperback 'The Recovery Run' follows Jensen Larsen, a visually impaired runner training for her first 26-mile marathon with a sighted guide.
Stargardt disease shapes the novel's perspective, shifting attention from visual cues to voice, touch and the risks of loud, unfamiliar spaces.
When Jensen's brother and original guide is injured, Garrett Marlowe steps in, and the rope-linked training becomes the basis for trust, old wounds and romance.
The review frames the book as a romance that treats disability as a lived reality rather than an obstacle that must disappear before a happy ending.

Sources

Left100%

The New York Times5h ago

Melissa Whitney's 'The Recovery Run' Novel Reviewed, Features Visually Impaired Marathoner

How does a 26-mile marathon tethered by a single rope transform a story of progressive vision loss into a gripping tale of desire?

Why is the literary world buzzing about a romance novel that refuses to treat its protagonist's incurable blindness as a problem to solve?

With a breakthrough Stargardt treatment nearing FDA approval in 2027, will the lived reality in this groundbreaking romance novel soon become history?

Sources

1 total

Left100%

The New York Times5h ago

Melissa Whitney's 'The Recovery Run' Novel Reviewed, Features Visually Impaired Marathoner

Melissa Whitney's 354-Page 'The Recovery Run' Centers Visually Impaired Marathoner

Summary

Sources

Insights

Sources